Quantitative Analysis of Favipiravir Spiked in Plasma Using by HPLC

Introduction

As of 2020, the development of both pharmaceuticals and vaccines remains urgent to overcome the global coronavirus disease 2019 (COVID-19) pandemic. Favipiravir (brand name: Avigan®), a promising drug candidate for COVID-19, is classified as an antiinfluenza drug, evaluated and developed for both novel and re-emerging influenza viruses.Favipiravir undergoes renal excretion, eliminated in the urine mainly as a hydroxide. Notably, the plasma levels of this drug are difficult to control owing to its once daily dosing regimen.Consequently, the accurate monitoring of drug levels is crucial. In this report, we introduce a unique approach for the quantitative high sensitivity plasma analysis of favipiravir using only a standard high-pressure liquid chromatography (HPLC) setup without mass spectrometry.

August 21, 2020 GMT